2 ASX shares tipped to grow up to 122% in the next 12 months

These companies could be on the cusp of something big.

Neither of the stocks I'm looking at today has performed well over the past 12 months, but that's not altogether surprising as both are in the ramp-up phase.

That's definitely a good thing, as it means there's plenty of upside to be had, provided the companies can derisk their projects and start generating real revenue.

These two companies are very different, with one being a mine project developer and the other having built an image analysis solution which helps diagnose heart problems.

Medical workers examine an x-ray or scan in a hospital laboratory.

Image source: Getty Images

New lithium hopeful emerges

The first company, Delta Lithium Ltd (ASX: DLI), is currently worth just $100.8 million, so it's firmly in small-cap territory.

On 13 November, Delta released a scoping study for its Mt Ida lithium project, which envisages a mine running for 11 years and generating $1.4 billion in free cash flow.

Given it's at the scoping study stage, there's plenty more work to be done, but on the positive side of the ledger, the project is fully permitted for both open pit and underground mining.

Managing Director James Croser said in a statement to the ASX on 17 November that the project also contained valuable tantalum and rubidium in the ore, with only minor changes to the processing method needed to separate them.

He said from now on:

Several value-adding activities will follow, including resource definition drilling, continued optimisation of the process flowsheet to reduce capital and operating costs and building upon work earlier this year on downstream recovery of rubidium and lithium carbonate from the lepidolite concentrate, with a firm view to maximising project potential for shareholders. Now that the scope of a potential lithium mine at Mt Ida has been outlined, Delta is well positioned to engage positively with industry partners on shared outcomes.

Bell Potter, in a research note published on 17 November, said it had reduced its price target for Delta from 41 cents to 30 cents in light of recent macroeconomic events.

This would still be a 122% return from the current level of 13.5 cents if achieved. The stock has fallen 40% over the past 12 months.

Heart imaging set to take off

Now turning to Artrya Ltd (ASX: AYA), which has experienced a 10.7% share price fall over the past year.

At the company's annual general meeting on 13 November, Chair Bernard Ridgeway said Artrya had shifted its focus to commercial execution about a year ago, and good progress was being made on that front.

The company had signed multi-year commercial contracts with five US health systems, "and we are in the early stages of a revenue-generating business''.

He added:

Artrya is targeting a market in the US that is large and growing every day. The U.S. market for CCTA scans is currently worth around US$4.4 billion a year and growing at a significant rate. The significant growth presents an immediate and genuine challenge for all health systems in the US. Volumes of scans are rising faster than the staffing and reporting capacity required to process them, and the legacy approach of manual scan reads is simply too slow to keep pace. Hospitals are currently carrying the cost and burden of an overwhelming number of patients with chest pain, and they need a simple and highly scalable technology solution.

Artrya's Salix Coronary Anatomy was built to address this problem, he said.

Morgans has rated the company a speculative buy, with a price target of $4.70, compared with $2.59 currently.

If realised, that would be an 81.5% return.

Morgans said it rates the management highly, "and the market is attractive, but it is early commercialisation and the pace of adoption is the swing factor''.

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

Thumbs down Facebook icon over dark screen.
Broker Notes

Why these 5 ASX shares were downgraded by brokers this week

Market analysts explain why they've downgraded these ASX stocks.

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

Buy, hold, sell: Domino's Pizza, Super Retail, PLS shares

Let's check out some new ratings on ASX shares today.

Read more »

Smiling woman taking a video through a plane window with her phone.
Broker Notes

Qantas or Virgin shares. Which ASX airline has more upside?

Will either share take off soon?

Read more »

A little girl wearing wonky glasses checks out what's happening in the world on a mobile phone.
Broker Notes

Buy, hold, sell: Paladin Energy, Accent, Sigma Healthcare shares

Experts reveal the reasons behind their new ratings.

Read more »

A woman looks excited as she fans out a wad of Aussie $100 notes.
Broker Notes

Macquarie predicts 90% upside and an 8% dividend yield for this ASX share

If the broker is right, this share will pay off nicely.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Young man with a laptop in hand watching stocks and trends on a digital chart.
Broker Notes

Buy, hold, sell: Fortescue, Santos, CBA shares

Let's review some new expert ratings and insights on 3 ASX 200 heavyweights.

Read more »